The financial impact of COVID-19 on healthcare providers has been considerable. With experts predicting that half of all US hospitals would be operating in the red by the end of 2020, healthcare leaders have had to seek multiple ways to cut costs.
The expansion of single-use medical device (SUD) reprocessing programs is seen as low-hanging fruit for healthcare institutions to control costs. For example, one report found hospitals could save $532 million by expanding electrophysiology reprocessing programs alone.
Leaders at Mayo Clinic in Rochester, Minnesota, recognized 20 years ago that some medical devices, labeled for single use by the manufacturer, could be safely reprocessed and used again. The change saves money and reduces environmental impact, with no risk to patient safety.
Third-party reprocessors applied for and received 510k product clearances from the US Food and Drug Administration (FDA), ensuring that the reprocessed devices were “substantially equivalent” to original devices. Over the years, the development of a SUD program at Mayo Clinic has yielded cost savings and environmental benefits, kept medical device assets in a reliable delivery network, and minimized import interruptions that have challenged the supply chain during the pandemic. Today, more than 300 SUDs have FDA clearances for reprocessing, and that number continues to grow.
Mayo Clinic’s reprocessing program began out of efforts to provide cost-effective products and promote sustainability by minimizing the volume of products that enter the waste stream. During the COVID-19 pandemic, Mayo Clinic and other healthcare providers have experienced disruptions in product availability that can impact patient care. Because the use of reprocessed devices helps to limit disruptions, the reprocessing program’s value has expanded beyond savings and waste reduction to include greater efficiency.
Mayo Clinic’s experience illustrates an opportunity for hospitals and health systems to align with reprocessor and original equipment manufacturers (OEMs) to meet inventory needs and to build a more resilient supply chain.
Growing our SUD reprocessing program responsibly and effectively took planning and careful coordination. By sharing our experience, we hope to help other hospitals interested in adopting a similar program.
Our reprocessing program is offered and driven by Captis, a member-owned and governed collaborative network of more than 90 Vizient health systems across the nation. Mayo Clinic is both a service provider and participating member in this network.
The rudder that steers the success of this program is the strategy statement, which ensures that reprocessing efforts will support clinical outcomes, including patient safety, while reducing supply expenses and increasing supply chain value across applicable categories. It calls for solutions that enhance value to reduce the cost of purchasing medical devices from OEMs as well as diversion of unnecessary materials from the waste stream.
The program consists of representatives from Captis member hospitals, Captis management, and the reprocessors, all of whom play roles in the partnership and governance of the program.
For the Captis management team, a key output is quarterly reprocessing reports that identify current value and missed opportunities. These reports are shared with supply chain and finance leaders.
Captis’ approach is focused on meeting diverse hospital needs and overcoming barriers to participation. Key to the program’s success has been the buy-in from numerous levels of management, including physicians, administrators, and nursing leaders across every campus and location.
The Captis program requires each health system to form a cross-disciplinary Sponsorship Team, which consists of individuals with expertise in value analysis, procurement, and logistics—including reprocessor representatives—to participate in an ongoing and structured governance.
Mayo Clinic’s Sponsorship Team meets monthly to monitor all aspects of the reprocessing program, review program targets, and develop a priority list and timetable for introducing new reprocessing product opportunities.

Cardiac mapping catheters are among the 300+ devices labeled for “single use” that are reprocessed for safe reuse at US hospitals. Photo courtesy of the Association of Medical Device Reprocessors.
A Reprocessing Action Plan, managed by the provider in partnership with the reprocessor, includes reprocessing targets. Initial product targets included electrophysiology catheters, vessel sealing devices, and ultrasonic activated cutting devices, like the Harmonic Scalpel.
The plan makes the business case for the program by outlining cost reductions, operational efficiency, and revenue streams. The ongoing conversation with stakeholders allows the Mayo Clinic Sponsorship Team to refine goals, clarify expectations, and obtain feedback to help the team improve the program.
The governance structure has served Captis and its members well, and we recommend that member hospitals and those contemplating a reprocessing program follow similar practices. This ensures the program’s value is understood across leadership and creates a secure, sustained pathway for successful adoption or expansion.
At Captis, we have identified several program roles, including:
• An implementation lead, who manages the relationship with our reprocessing vendor, updates the sponsorship team as reprocessors receive new 510k clearances, and facilitates two-way discussions for expansion and improvements.
• A quality lead, who oversees monitoring, resolves perceived and reported quality concerns, and reports on a monthly basis to both the Captis Program and Mayo Sponsorship team.
• A value analysis lead, who oversees standardization and formulary management, including value-added efforts, drives educational offerings to new staff, and expands awareness across departments.
• A financial analysis lead, who records and manages all financial aspects and metrics, and scores the program monthly. The financial analysis lead identifies gaps and changes in data that indicate a potential problem or a success.
• A contract management lead, who acts as the conduit between OEMs and reprocessors to implement the will of our sponsorship team.
The Reprocessing Action Plan requires all original equipment suppliers to confirm that their goals are aligned with those of our reprocessing program, including clinical outcomes and the desire to help hospitals increase financial security and decrease waste. As part of the Mayo Clinic and Captis sourcing and contracting process, reprocessing terms are negotiated up front to closely match our values and ensure program goals are prioritized.
The Captis team educates manufacturers on our reprocessing objectives, including cost-effective and environmentally sound patient care. As health systems across the nation grapple with meeting the needs of patients in a cost-effective manner and boosting supply chain resiliency, reprocessing offers a viable pathway if a structured program approach, aligned resources, and willing OEMs are identified.
Hospital and surgical center acceptance of reprocessed devices has been impressive. Given that FDA regulation of reprocessing began in 1998, the growth of reprocessing has been breathtaking. Today, more than 7,300 hospitals in North America use reprocessing companies to help collect, sort, label, clean, disinfect, test, sterilize, package, and return SUDs to hospitals for safe use.
In 2018, reprocessing saved hospitals more than $470 million, and SUD reprocessing eliminated more than 16 million pounds of medical waste. According to the Association of Medical Device Reprocessors, cost savings by hospitals and surgical centers from reprocessing have doubled each year for 20 consecutive years.
The Mayo Clinic mission and values date back to the founders of the organization, who stated: “The needs of the patient come first.” They defined stewardship as sustaining and reinvesting in [Mayo’s] mission and extended communities “by wisely managing our human, natural, and material resources.” They believed this philosophy must be central to daily management and future planning.
In many ways, Mayo Clinic’s value analysis team has been preparing for an emergency such as COVID-19 for years. We have identified ways to generate cost savings and achieve our value equation, including product standardization, maximizing product utilization, and product formularies. The financial benefits have been invested in staff, equipment, and emergency supplies.
With the right roadmap, hospitals in urgent need of financial savings need look no further than SUD reprocessing to save hundreds of millions of dollars. ✥